Is IKT or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Avalyn Pharma N/A N/A N/A

Does the media prefer IKT or AVLN?

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 2 mentions for Avalyn Pharma. Inhibikase Therapeutics' average media sentiment score of 1.34 beat Avalyn Pharma's score of 0.05 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IMTX or IKT?

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than Immatics. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 2 mentions for Immatics. Inhibikase Therapeutics' average media sentiment score of 1.34 beat Immatics' score of 1.14 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibikase Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INBX or IKT more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -72.32% Inhibikase Therapeutics N/A -41.31% -38.98%

Does the media refer more to INBX or IKT?

In the previous week, Inhibrx Biosciences and Inhibrx Biosciences both had 4 articles in the media. Inhibikase Therapeutics' average media sentiment score of 1.34 beat Inhibrx Biosciences' score of 0.91 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Inhibikase Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CALT or IKT?

Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 144.34%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Inhibikase Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.00

Does the media favor ETON or IKT?

In the previous week, Eton Pharmaceuticals had 3 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 7 mentions for Eton Pharmaceuticals and 4 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.34 beat Eton Pharmaceuticals' score of 0.21 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibikase Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inhibikase Therapeutics (IKT) Competitors

$2.21 +0.03 (+1.38%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$2.18 -0.03 (-1.36%)

As of 08/3/2026 07:55 PM Eastern

Compare

IKT vs. AVLN, IMTX, INBX, CALT, and ETON

Should you buy Inhibikase Therapeutics stock or one of its competitors? MarketBeat compares Inhibikase Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inhibikase Therapeutics include Avalyn Pharma (AVLN), Immatics (IMTX), Inhibrx Biosciences (INBX), Calliditas Therapeutics AB (publ) (CALT), and Eton Pharmaceuticals (ETON).

How does Inhibikase Therapeutics compare to Avalyn Pharma?

Inhibikase Therapeutics (NASDAQ:IKT) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 2 mentions for Avalyn Pharma. Inhibikase Therapeutics' average media sentiment score of 1.34 beat Avalyn Pharma's score of 0.05 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avalyn Pharma has lower revenue, but higher earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,122.26	-$48.26M	-$0.43	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

Inhibikase Therapeutics presently has a consensus price target of $5.40, suggesting a potential upside of 144.34%. Avalyn Pharma has a consensus price target of $59.00, suggesting a potential upside of 107.02%. Given Inhibikase Therapeutics' higher possible upside, equities research analysts clearly believe Inhibikase Therapeutics is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Avalyn Pharma's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Avalyn Pharma	N/A	N/A	N/A

3.8% of Inhibikase Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Inhibikase Therapeutics beats Avalyn Pharma on 9 of the 13 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Immatics?

Immatics (NASDAQ:IMTX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Immatics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Inhibikase Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Inhibikase Therapeutics' return on equity of -41.31% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

Immatics presently has a consensus target price of $20.80, indicating a potential upside of 130.60%. Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 144.34%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

64.4% of Immatics shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than Immatics. MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 2 mentions for Immatics. Inhibikase Therapeutics' average media sentiment score of 1.34 beat Immatics' score of 1.14 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibikase Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibikase Therapeutics has lower revenue, but higher earnings than Immatics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	22.15	-$222.26M	-$1.99	N/A
Inhibikase Therapeutics	$260K	1,122.26	-$48.26M	-$0.43	N/A

Summary

Inhibikase Therapeutics beats Immatics on 12 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Inhibikase Therapeutics has lower revenue, but higher earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	933.46	-$140.05M	-$8.39	N/A
Inhibikase Therapeutics	$260K	1,122.26	-$48.26M	-$0.43	N/A

Inhibrx Biosciences has a beta of 3.51, meaning that its share price is 251% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

In the previous week, Inhibrx Biosciences and Inhibrx Biosciences both had 4 articles in the media. Inhibikase Therapeutics' average media sentiment score of 1.34 beat Inhibrx Biosciences' score of 0.91 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibikase Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences currently has a consensus price target of $150.00, indicating a potential upside of 81.33%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 144.34%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Inhibikase Therapeutics' return on equity of -41.31% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Inhibikase Therapeutics beats Inhibrx Biosciences on 11 of the 15 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Inhibikase Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Inhibikase Therapeutics' return on equity of -41.31% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

In the previous week, Inhibikase Therapeutics had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Inhibikase Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Inhibikase Therapeutics' average media sentiment score of 1.34 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Inhibikase Therapeutics	Positive

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Inhibikase Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Inhibikase Therapeutics	$260K	1,122.26	-$48.26M	-$0.43	N/A

Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 144.34%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Inhibikase Therapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Inhibikase Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

Eton Pharmaceuticals has higher revenue and earnings than Inhibikase Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	15.46	-$4.60M	-$0.07	N/A
Inhibikase Therapeutics	$260K	1,122.26	-$48.26M	-$0.43	N/A

Eton Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Eton Pharmaceuticals presently has a consensus target price of $52.50, indicating a potential upside of 16.30%. Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 144.34%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Eton Pharmaceuticals had 3 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 7 mentions for Eton Pharmaceuticals and 4 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.34 beat Eton Pharmaceuticals' score of 0.21 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibikase Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Inhibikase Therapeutics beats Eton Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IKT vs. The Competition

Export

Metric	Inhibikase Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$287.83M	$11.61B	$6.86B	$12.43B
Dividend Yield	N/A	2.73%	2.60%	10.03%
P/E Ratio	-5.14	793.98	280.72	24.99
Price / Sales	1,122.26	942.39	644.56	112.42
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	0.96	10.45	11.07	6.21
Net Income	-$48.26M	$2.80B	$3.48B	$347.49M
7 Day Performance	-4.33%	0.77%	0.83%	1.28%
1 Month Performance	11.06%	-3.79%	-4.14%	-3.62%
1 Year Performance	N/A	154.77%	61.50%	18.37%

Inhibikase Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IKT Inhibikase Therapeutics	3.6543 of 5 stars	$2.21 +1.4%	$5.40 +144.3%	N/A	$287.83M	$260K	N/A	6	Positive News
AVLN Avalyn Pharma	2.8566 of 5 stars	$27.62 -1.2%	$59.00 +113.6%	N/A	$1.22B	N/A	N/A	51
IMTX Immatics	2.5687 of 5 stars	$8.63 -5.0%	$20.80 +141.0%	+39.2%	$1.22B	$54.60M	N/A	260	Positive News
INBX Inhibrx Biosciences	2.6788 of 5 stars	$82.45 +1.1%	$150.00 +81.9%	+283.0%	$1.20B	$1.30M	N/A	166	Positive News Analyst Downgrade
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IKT) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibikase Therapeutics (IKT) Competitors

IKT vs. AVLN, IMTX, INBX, CALT, and ETON

How does Inhibikase Therapeutics compare to Avalyn Pharma?

Summary

How does Inhibikase Therapeutics compare to Immatics?

Summary

How does Inhibikase Therapeutics compare to Inhibrx Biosciences?

Summary

How does Inhibikase Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibikase Therapeutics (IKT) Competitors

IKT vs. AVLN, IMTX, INBX, CALT, and ETON

How does Inhibikase Therapeutics compare to Avalyn Pharma?

Does the media prefer IKT or AVLN?

Which has preferable valuation & earnings, IKT or AVLN?

Do analysts rate IKT or AVLN?

Is IKT or AVLN more profitable?

Do insiders & institutionals hold more shares of IKT or AVLN?

Summary

How does Inhibikase Therapeutics compare to Immatics?

Which has more risk & volatility, IMTX or IKT?

Is IMTX or IKT more profitable?

Do analysts recommend IMTX or IKT?

Do insiders and institutionals believe in IMTX or IKT?

Does the media favor IMTX or IKT?

Which has better valuation & earnings, IMTX or IKT?

Summary

How does Inhibikase Therapeutics compare to Inhibrx Biosciences?

Which has higher earnings and valuation, INBX or IKT?

Which has more risk and volatility, INBX or IKT?

Does the media refer more to INBX or IKT?

Do analysts prefer INBX or IKT?

Is INBX or IKT more profitable?

Do institutionals & insiders believe in INBX or IKT?

Summary

How does Inhibikase Therapeutics compare to Calliditas Therapeutics AB (publ)?

Is CALT or IKT more profitable?

Which has more volatility and risk, CALT or IKT?

Does the media refer more to CALT or IKT?

Which has preferable valuation and earnings, CALT or IKT?

Do analysts prefer CALT or IKT?

Do institutionals and insiders believe in CALT or IKT?

Summary

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Is ETON or IKT more profitable?

Which has preferable earnings and valuation, ETON or IKT?

Which has more risk and volatility, ETON or IKT?

Do analysts prefer ETON or IKT?

Does the media favor ETON or IKT?

Do insiders & institutionals have more ownership in ETON or IKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools